Mammoth Biosciences has secured an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its CRISPR-based SARS-CoV-2 test kit. The high-throughput test is the first of its kind, Mammoth Biosciences said.
The company's Detectr Boost assay works with Agilent's Bravo BenchCel DB liquid handling platform and identifies SARS-CoV-2 RNA in nasal swab specimens from people suspected to have COVID-19, according to the firm. It is performed in a laboratory.
